Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis - PubMed (original) (raw)
Review
Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis
Xiaoning Gan et al. Dis Markers. 2016.
Abstract
p16, encoded by the CDKN2A gene, is a tumor suppressor that has been widely studied in cancer research. However, the relationship of p16 with prognostic and clinicopathological parameters in patients with bladder cancer remains unclear. Data inclusion criteria were articles reporting on the relationship between p16 expression and the prognosis or clinicopathology in patients with bladder cancer. Meta-analyses were performed with Stata software. Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated to evaluate the relative risks. The source of heterogeneity was analyzed by subgroup analysis. A total of 37 studies with 2246 cases were included and analyzed. The results identified an important link between downregulated p16 expression and poor prognosis in patients with bladder cancer in terms of recurrence-free survival (RFS), overall survival (OS), progression-free survival (PFS), and some clinicopathological parameters including clinical staging, pathological degree, and lymph node metastasis. Subgroup analysis also showed that low p16 expression could function as a warning sign for RFS and PFS in patients with early-stage (Ta-T1) bladder cancer. In conclusion, p16 might play an essential role in the deterioration of bladder cancer and could serve as a biomarker for the prediction for patients' progression and prognosis.
Figures
Figure 1
Main molecular pathways of bladder cancer (adapted from Mitra et al. [7]).
Figure 2
Flow diagram of studies selection procedure.
Figure 3
Forrest plot of hazard ratio (HR) for the association of p16 with recurrence-free survival (RFS) (a), overall survival (OS) (b), and progression-free survival (PFS) (c) in patients with bladder cancer.
Figure 4
The funnel plot of the meta-analysis of the impact of p16 expression on recurrence-free survival (RFS) (a), overall survival (OS) (b), and progression-free survival (PFS) (c) in patients with bladder cancer.
Figure 5
Our results illustrated and improved the relationship between p16 and prognosis, as well as clinicopathological features.
Similar articles
- Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis.
Sun L, Song J, Huang Q. Sun L, et al. Medicine (Baltimore). 2019 Mar;98(11):e14602. doi: 10.1097/MD.0000000000014602. Medicine (Baltimore). 2019. PMID: 30882625 Free PMC article. - Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
Yurakh AO, Ramos D, Calabuig-Fariñas S, López-Guerrero JA, Rubio J, Solsona E, Romanenko AM, Vozianov AF, Pellin A, Llombart-Bosch A. Yurakh AO, et al. Eur Urol. 2006 Sep;50(3):506-15; discussion 515. doi: 10.1016/j.eururo.2006.03.027. Epub 2006 Mar 31. Eur Urol. 2006. PMID: 16624482 - Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer.
Tang K, Wang C, Chen Z, Xu H, Ye Z. Tang K, et al. Int J Clin Exp Pathol. 2015 May 1;8(5):4999-5007. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26191193 Free PMC article. - Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis.
Miao C, Liang C, Zhu J, Xu A, Zhao K, Hua Y, Zhang J, Chen W, Suo C, Zhang C, Liu Y, Su S, Wang Z. Miao C, et al. Oncotarget. 2017 May 9;8(19):32309-32321. doi: 10.18632/oncotarget.15907. Oncotarget. 2017. PMID: 28427222 Free PMC article. Review. - P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.
Tang Y, Yang C, Guo Z, Fu Y, Yu X, Liu B, Zhou H, Wang J, Li W, Pang Q. Tang Y, et al. Medicine (Baltimore). 2017 May;96(19):e6714. doi: 10.1097/MD.0000000000006714. Medicine (Baltimore). 2017. PMID: 28489748 Free PMC article. Review.
Cited by
- The Prevalence of p16 Expression in Urothelial Bladder Cancer in a Tertiary Care Hospital of Chattogram, Bangladesh.
Farnaz T, Bhattacharjee P, Ahamad MSU, Rima SA, Momin NN, Sadaf A. Farnaz T, et al. Iran J Pathol. 2023 Summer;18(3):306-311. doi: 10.30699/IJP.2023.1987551.3070. Epub 2023 Jul 16. Iran J Pathol. 2023. PMID: 37942193 Free PMC article. - Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.
Sanguedolce F, Zanelli M, Palicelli A, Ascani S, Zizzo M, Cocco G, Björnebo L, Lantz A, Landriscina M, Conteduca V, Falagario UG, Cormio L, Carrieri G. Sanguedolce F, et al. Int J Mol Sci. 2022 Jul 16;23(14):7844. doi: 10.3390/ijms23147844. Int J Mol Sci. 2022. PMID: 35887192 Free PMC article. Review. - Bladder cancer survival in patients with NOD2 or CDKN2A variants.
Złowocka-Perłowska E, van de Wetering T, Tołoczko-Grabarek A, Scott RJ, Lubiński J. Złowocka-Perłowska E, et al. Oncotarget. 2022 Apr 22;13:628-640. doi: 10.18632/oncotarget.28226. eCollection 2022. Oncotarget. 2022. PMID: 35478773 Free PMC article. - The LncRNA DUXAP10 Could Function as a Promising Oncogene in Human Cancer.
Zhao J, Xu L, Dong Z, Zhang Y, Cao J, Yao J, Xing J. Zhao J, et al. Front Cell Dev Biol. 2022 Feb 3;10:832388. doi: 10.3389/fcell.2022.832388. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35186937 Free PMC article. Review. - Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.
Jackson CL, Chen L, Hardy CS, Ren KY, Visram K, Bratti VF, Johnstone J, Sjödahl G, Siemens DR, Gooding RJ, Berman DM. Jackson CL, et al. J Pathol Clin Res. 2022 Mar;8(2):143-154. doi: 10.1002/cjp2.245. Epub 2021 Oct 26. J Pathol Clin Res. 2022. PMID: 34697907 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous